secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097548
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris releases corporate presentation with TH103 trial updates but no specific figures disclosed
--------------------------------------------------------------------------------

- Presentation includes timelines for reporting Phase 1b/2 data of TH103 and plans to initiate Phase 3; no dates or numbers given in filing.
- Cash runway guidance mentioned in the presentation; precise amount or duration not provided in the 8-K.
- Presentation to be used at Leerink Partners Global Healthcare Conference and other investor meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526097548/0001193125-26-097548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526097548/d122695d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer